ENTRY       K06621                      KO
NAME        CDKN2A, P16, INK4A
DEFINITION  cyclin-dependent kinase inhibitor 2A
PATHWAY     ko04110  Cell cycle
            ko04115  p53 signaling pathway
            ko05166  HTLV-I infection
            ko05200  Pathways in cancer
            ko05203  Viral carcinogenesis
            ko05206  MicroRNAs in cancer
            ko05212  Pancreatic cancer
            ko05214  Glioma
            ko05218  Melanoma
            ko05219  Bladder cancer
            ko05220  Chronic myeloid leukemia
            ko05223  Non-small cell lung cancer
DISEASE     H00004  Chronic myeloid leukemia (CML)
            H00008  Burkitt lymphoma
            H00009  Adult T-cell leukemia
            H00014  Non-small cell lung cancer
            H00015  Malignant pleural mesothelioma
            H00016  Oral cancer
            H00017  Esophageal cancer
            H00019  Pancreatic cancer
            H00022  Bladder cancer
            H00025  Penile cancer
            H00036  Osteosarcoma
            H00038  Malignant melanoma
            H00040  Squamous cell carcinoma
            H00042  Glioma
            H00045  Malignant islet cell carcinoma
            H00046  Cholangiocarcinoma
            H00047  Gallbladder cancer
            H00048  Hepatocellular carcinoma
            H00054  Nasopharyngeal cancer
            H00055  Laryngeal cancer
            H00409  Type II diabetes mellitus
BRITE       KEGG Orthology (KO) [BR:ko00001]
             Cellular Processes
              Cell growth and death
               04110 Cell cycle
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
               04115 p53 signaling pathway
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
             Human Diseases
              Cancers
               05200 Pathways in cancer
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
               05206 MicroRNAs in cancer
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
               05203 Viral carcinogenesis
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
               05212 Pancreatic cancer
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
               05214 Glioma
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
               05220 Chronic myeloid leukemia
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
               05218 Melanoma
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
               05219 Bladder cancer
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
               05223 Non-small cell lung cancer
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
              Infectious diseases
               05166 HTLV-I infection
                K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
DBLINKS     GO: 0004861
GENES       HSA: 1029(CDKN2A)
            PTR: 465021(CDKN2A)
            PPS: 100975637
            GGO: 101145463(CDKN2A)
            PON: 100461015
            MCC: 709988
            MCF: 102135474(CDKN2A)
            MMU: 12578(Cdkn2a)
            RNO: 25163(Cdkn2a)
            CGE: 100764983
            CFA: 100271861(CDKN2A)
            AML: 100472171
            FCA: 101089220(CDKN2A)
            BTA: 616369(CDKN2A)
            BOM: 102284461(CDKN2A)
            ECB: 100146270(CDKN2A)
            OAA: 100083932
            ACS: 100562668
REFERENCE   PMID:9724636
  AUTHORS   Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G
  TITLE     The alternative product from the human CDKN2A locus, p14(ARF), participates in a  regulatory feedback loop with p53 and MDM2.
  JOURNAL   EMBO J 17:5001-14 (1998)
///
